| 000 | 01195 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250513211555.0 | ||
| 264 | 0 | _c20000512 | |
| 008 | 200005s 0 0 eng d | ||
| 022 | _a0003-4819 | ||
| 024 | 7 |
_a10.7326/0003-4819-132-10-200005160-00012 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGarber, A M | |
| 245 | 0 | 0 |
_aUsing cost-effectiveness analysis to target cholesterol reduction. _h[electronic resource] |
| 260 |
_bAnnals of internal medicine _cMay 2000 |
||
| 300 |
_a833-5 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Editorial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAnticholesteremic Agents _xeconomics |
| 650 | 0 | 4 | _aCost of Illness |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xeconomics |
| 650 | 0 | 4 |
_aHypercholesterolemia _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 773 | 0 |
_tAnnals of internal medicine _gvol. 132 _gno. 10 _gp. 833-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.7326/0003-4819-132-10-200005160-00012 _zAvailable from publisher's website |
| 999 |
_c10771395 _d10771395 |
||